CN112641856A - Anti-aging traditional Chinese medicine composition - Google Patents
Anti-aging traditional Chinese medicine composition Download PDFInfo
- Publication number
- CN112641856A CN112641856A CN202011591031.0A CN202011591031A CN112641856A CN 112641856 A CN112641856 A CN 112641856A CN 202011591031 A CN202011591031 A CN 202011591031A CN 112641856 A CN112641856 A CN 112641856A
- Authority
- CN
- China
- Prior art keywords
- extract
- weight
- parts
- skin
- ginseng
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Abstract
The invention discloses an anti-aging traditional Chinese medicine composition, which comprises the following components in parts by weight: 1-10 parts of saffron extract, 15-40 parts of ginseng extract, 15-35 parts of lotus extract, 15-30 parts of giant knotweed extract, 10-25 parts of ligusticum wallichii extract and 10-25 parts of Chinese angelica extract, wherein the saffron extract, the ginseng extract, the lotus extract, the giant knotweed extract, the ligusticum wallichii extract and the Chinese angelica extract are prepared by a solvent ultrasonic extraction method. The invention also provides a preparation method and application of the anti-aging traditional Chinese medicine composition.
Description
Technical Field
The invention relates to the field of natural medicinal chemistry and cosmetics, in particular to a traditional Chinese medicine composition with an anti-aging effect, and a preparation method and application thereof.
Background
Anti-aging cosmetics have been of interest in the cosmetics industry because the problem of resisting skin aging is a major concern and protecting and retarding skin aging is a dream for many people. Skin aging is a continuous and progressive physiological process that directly affects the appearance and function of the skin.
Non-enzymatic glycosylation NEG is a complex series of non-enzymatic reactions in which reducing sugars are directly bound to protein residues to produce Schiff bases (Schiff), which are cleaved into glucosamine rearrangement (Amadori) products, which are subsequently dehydrated, cyclized, oxidized and rearranged to further degrade into a series of reactive aldehyde ketone compounds (reactive carbonyl compounds RCS). RCS has higher activity than reducing sugars, and can rapidly combine with free amino groups of proteins to finally generate irreversible brown yellow substances with fluorescence properties, which are collectively called Advanced Glycation End products (AGEs).
Human skin tissue contains a large amount of collagen and elastin. These two proteins are slowly metabolized and contain more lysine and hydroxylysine, which provides a material basis for the NEG reaction to take place. Skin proteins and reducing sugars undergo NEG to form AGEs, which increase with age. As AGEs increase, collagen forms intermolecular crosslinks that reduce the permeability of connective tissue, but also reduce the diffusion of nutrients and waste, and increase tissue ductility and stiffness; the solubility of collagen is reduced and it is difficult to be hydrolyzed by collagenase, resulting in decrease in skin elasticity and generation of wrinkles, and deepening with age.
Oxidation is a crucial step in the formation of AGEs. The intermediate products, mono-reactive carbonyl (dicarbonyl) groups formed by AEGs, such as malondialdehyde MDA, 3-deoxyglucuronal 3-deoxyglucome, are all degraded by or autooxidized from the Amadori product. AGEs can directly reduce the activity of antioxidant enzymes in vivo. Increasing the oxidative stress level of the skin. Overall, oxidative stress can promote NEG processes, and AGEs can increase oxidative stress levels. In fact, many antioxidants have been shown to have anti-glycation activity, such as: ascorbic acid, tocopherol, sodium selenite, riboflavin, zinc, manganese and the like are found to have an anti-saccharification effect in vitro experiments. The mixture of green tea, Vitamin C (VC), Vitamin E (VE), acetylcysteine and rutin can inhibit non-enzymatic glycation of collagen in skin of mice.
Currently, there are known AGEs in structural form: carboxymethyl lysine (CML), carboxyethyl lysine (CEL), pentosidin, glycosylated collagen, pyrrol, and dillysyl imidazoline derivatives, and the like. Most of them have fluorescence specificity (such as pentosidin and glycosylated acrogen) and some of them have no fluorescence property (such as CML and CEL). Therefore, for the evaluation of the anti-glycation efficacy, the biochemical reaction method is adopted, namely, a bovine serum albumin-glucose (BSA-glucose) model, a bovine serum albumin-methylglyoxal (BSA-MGO) model and the like are adopted, the content of AGEs after the reaction is evaluated by a fluorescence spectrophotometry method, and in addition, the detection of the main structure type carboxymethyl lysine of the AGEs is carried out by an immunohistochemical method based on the in vitro skin, so that the anti-glycation efficacy is evaluated.
Thus, various pathways and substances have been proposed to positively influence elastin and the skin properties associated therewith. However, the present inventors have unexpectedly found that a Chinese medicinal composition comprising extracts of saffron, ginseng, lotus, polygonum cuspidatum, ligusticum wallichii, and angelicae sinensis has excellent antioxidant and good anti-glycosylation effects.
Disclosure of Invention
In one aspect, the present invention provides an anti-aging Chinese medicinal composition, comprising:
1-10 parts by weight of saffron extract,
15-40 parts by weight of a ginseng extract,
15-35 parts by weight of a lotus extract,
15-30 parts by weight of a giant knotweed extract,
10-25 parts by weight of a ligusticum wallichii extract,
10-25 parts by weight of an angelica extract,
wherein the stigma croci Sativi extract, Ginseng radix extract, flos Nelumbinis extract, rhizoma Polygoni Cuspidati extract, rhizoma Ligustici Chuanxiong extract, and radix Angelicae sinensis extract are prepared by solvent ultrasonic extraction method.
In a preferred embodiment, the weight ratio of the saffron extract, the ginseng extract, the lotus flower extract, the giant knotweed extract, the ligusticum wallichii extract and the angelica sinensis extract is 0.1-0.5:1-3:1-2:0.5-2:1-2: 1-2. In a more preferred embodiment, the weight ratio of the saffron extract, the ginseng extract, the lotus extract, the giant knotweed extract, the ligusticum wallichii extract and the angelica sinensis extract is 0.1:3:2:2:1: 1.
In a preferred embodiment or, the extract of the invention is extracted with ethanol, preferably 70% ethanol by volume.
In another aspect, the present invention relates to the use of a herbal composition comprising saffron extract, ginseng extract, lotus extract, polygonum cuspidatum extract, ligusticum wallichii extract, and angelicae gigantis radix extract for non-therapeutic anti-skin aging. In a preferred embodiment, the anti-skin aging is achieved by anti-oxidation and/or anti-glycosylation.
On the other hand, the invention also relates to the application of the traditional Chinese medicine composition containing the saffron extract, the ginseng extract, the lotus flower extract, the giant knotweed extract, the szechuan lovage rhizome extract and the Chinese angelica extract in preparing cosmetics for resisting skin aging. In a preferred embodiment, the anti-skin aging is achieved by anti-oxidation and/or anti-glycosylation.
In another aspect, the present invention relates to a method for preparing a Chinese medicinal composition comprising saffron extract, ginseng extract, lotus extract, giant knotweed extract, chuanxiong rhizome extract, and angelica extract, the method comprising:
respectively preparing a saffron extract, a ginseng extract, a lotus extract, a giant knotweed extract, a ligusticum wallichii extract and an angelica sinensis extract by adopting a solvent ultrasonic extraction method;
the saffron extract, the ginseng extract, the lotus extract, the giant knotweed extract, the ligusticum wallichii extract and the angelica sinensis extract are combined according to parts by weight.
In still another aspect, the present invention provides a skin external preparation comprising a Chinese medicinal composition comprising saffron extract, ginseng extract, lotus extract, polygonum cuspidatum extract, ligusticum wallichii extract, and angelicae gigantis radix extract. In a preferred embodiment, the external preparation for skin comprises 0.01 to 5% by weight of the Chinese medicinal composition.
Drawings
The invention is further described below with reference to the accompanying drawings.
FIG. 1 is a result of the relative expression levels of advanced glycation end products (AGEs). Wherein, BC represents a blank control, NC represents a negative control, and PC represents a positive control.
FIG. 2 shows the results of immunohistochemical assays. The microscope used was OLMPUS BX53 with a magnification of 20 objective × 10 eyepiece and 40 objective × 10 eyepiece respectively. Wherein, the picture of expression analysis is a picture of 40 times objective lens multiplied by 10 times ocular lens.
Detailed Description
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In addition, all publications, patent applications, patents, and other references mentioned herein are incorporated by reference. Percentages refer to weight percent unless otherwise indicated.
As used herein, "anti-aging" includes reducing, preventing, ameliorating, or eliminating the presence of such things as fine lines and wrinkles, loss of elasticity, skin unevenness, redness and age spots.
As used herein, "wrinkles" include fine lines, fine wrinkles or coarse wrinkles. Examples of wrinkles include, but are not limited to, fine lines around the eyes (e.g., "crow's feet"), forehead and cheek wrinkles, eyebrow lines, and smile lines around the mouth.
As used herein, "loss of elasticity" includes loss of elasticity or structural integrity of skin or tissue, including but not limited to sagging, laxity, and loose tissue. Loss of elasticity or structural integrity of a tissue can be caused by a variety of factors including, but not limited to, disease, aging, hormonal changes, mechanical trauma, environmental damage, or as a result of the application of a product such as cosmetics or pharmaceuticals to the tissue.
As used herein, "skin unevenness" refers to a skin condition associated with diffuse or mottled pigmentation that can be classified as hyperpigmentation, such as post-inflammatory hyperpigmentation.
As used herein, "erythema" refers to skin conditions associated with redness or erythema.
As used herein, "age spots" refer to skin conditions associated with discontinuous pigmentation, such as darker pigmented small areas that can develop on the face as well as on the hands.
As used herein, "cosmetic" refers to a cosmetic substance or article that maintains, restores, imparts, stimulates or enhances the appearance of a body beauty or appears to enhance the appearance or youthfulness, particularly with respect to the appearance of tissue or skin.
As used herein, a "cosmetically effective amount" refers to an amount of a physiologically active compound or composition that is sufficient to treat one or more signs of skin aging, but sufficiently low to avoid serious side effects. The cosmetically effective amount of the compound or composition will vary depending on the following factors: the particular condition being treated, the age and physical condition of the end user, the severity of the condition being treated/prevented, the duration of the treatment, the nature of the other treatment, the particular compound or product/composition employed, the cosmetically acceptable carrier specifically employed, and the like.
Stigma croci extract
The anti-aging traditional Chinese medicine composition comprises a saffron extract.
Saffron, a stigma of Crocus sativus l. Also named as saffron and crocus. Sweet in nature and mild in nature. It enters heart and liver meridians. Has the functions of promoting blood circulation to disperse blood clots, dispersing stagnation and eliminating stagnation. Modern researches show that saffron has the effects of resisting oxidation, resisting coagulation, regulating immunity and the like.
Although the application of the saffron extract is disclosed in the prior art, the efficacy of the saffron extract is not disclosed, and the efficacy and the application of the compound extract containing saffron are not disclosed. For example, CN110812299A discloses a toner always containing saffron and a preparation process thereof. For another example, CN106821932A discloses a cosmetic containing saffron extract, wherein the efficacy of the saffron extract is not disclosed. For another example, CN110279640A discloses that saffron extract has whitening effect.
In a preferred embodiment, the chinese medicinal composition of the present invention comprises 1 to 10 parts by weight, preferably 1 to 2 parts by weight of saffron extract.
Ginseng extract
The anti-aging traditional Chinese medicine composition comprises a ginseng extract.
Ginseng, is root of Panax ginseng C.A.Mey. Named as Huangshen, Yujing, Xuanshen, Haiershen, etc. Sweet in nature and slightly warm. It enters lung, spleen, heart and kidney meridians. Has effects of invigorating primordial qi, promoting fluid production, and tranquilizing mind. The literature reports that the main component of the ginseng and the preparation thereof is ginsenoside, which has remarkable promoting effects on improving learning ability and facilitating memory, and can inhibit staphylococcus aureus and improve autoimmunity. Besides, ginseng also has the effects of oxidation resistance, aging resistance and inflammation resistance.
Although the prior art discloses the application of extracts of ginseng root, ginseng flower seed and the like, the efficacy of ginseng, especially fresh ginseng extract is not disclosed, and the efficacy and the application of the compound extract containing fresh ginseng are not disclosed. For example, CN110787075A is a skin care oil composition containing ginseng root extract and ginseng seed oil, wherein the efficacy of ginseng root or ginseng seed oil is not disclosed.
In a preferred embodiment, the Chinese medicinal composition of the present invention comprises 15 to 40 parts by weight, preferably 15 to 35 parts by weight of ginseng extract.
Lotus extract
The anti-aging traditional Chinese medicine composition comprises a lotus extract.
The lotus is flower bud of Nelumbo nucifera Gaertn. Han 33807Han, lotus and cotton rose. Bitter, sweet and neutral in nature. It enters liver and stomach meridians. The lotus can dissipate blood stasis, stop bleeding, eliminate dampness and dispel wind. The lotus contains abundant flavone components, is a good antioxidant and bacteriostatic agent, and can clear superoxide anion free radicals and hydroxyl free radicals.
Although the application of lotus active substances is disclosed in the prior art, the efficacy of lotus, particularly lotus/lotus extract is not disclosed, and the efficacy and the application of the compound extract containing lotus/lotus in the invention are not disclosed. For example, CN105534815B discloses a skin care composition containing lotus active ingredients, wherein the specific efficacy of lotus active ingredients is not disclosed.
In a preferred embodiment, the traditional Chinese medicine composition of the present invention comprises 15 to 35 parts by weight, preferably 20 to 30 parts by weight of the lotus extract.
Polygonum cuspidatum extract
The anti-aging traditional Chinese medicine composition comprises a giant knotweed extract.
Rhizoma Polygoni Cuspidati is rhizome and root of Polygonum cuspidatum Sieb. Also known as canes, sticks, sour sticks, etc. Bitter in property and slightly cold in nature. It enters liver, gallbladder and lung meridians. Rhizoma Polygoni Cuspidati has effects of promoting blood circulation, removing blood stasis, and clearing away heat and toxic materials. Modern pharmacology indicates that the polygonum cuspidatum contains polydatin, can effectively inhibit lipid peroxidation caused by a free radical generation system, and also has antibacterial and antiviral effects.
Although the prior art discloses the giant knotweed rhizome extract and the application thereof, the efficacy and the application of the compound extract containing the giant knotweed rhizome in the invention are not disclosed. For example, CN111870572A discloses antioxidant effect of polygonum cuspidatum extract and its application.
In a preferred embodiment, the Chinese medicinal composition of the present invention comprises 15 to 30 parts by weight, preferably 15 to 25 parts by weight of the polygonum cuspidatum extract.
Ligusticum wallichii extract
The anti-aging traditional Chinese medicine composition comprises a ligusticum wallichii extract.
Rhizoma Ligustici Chuanxiong is rhizome of Ligusticum chuanxiong Hort. of Umbelliferae. Erichang Chuan Xiong
Xiangguo and Huhu
And the rhizome of chuanxiong. Pungent and warm in nature. It enters liver, gallbladder and pericardium meridians. Rhizoma Ligustici Chuanxiong has effects of promoting blood circulation, removing blood stasis, activating qi-flowing, resolving stagnation, dispelling pathogenic wind and relieving pain. The main component is ligustrazine, and has effects of resisting oxidation, resisting inflammation, promoting blood microcirculation, and enhancing immunity.
Also, the efficacy and use of the chuanxiong rhizome-containing compound extract of the present invention is disclosed in the prior art.
In a preferred embodiment, the present invention comprises 10 to 25 parts by weight, preferably 10 to 15 parts by weight of the extract of cnidium officinale Makino.
Angelica sinensis extract
The anti-aging traditional Chinese medicine composition comprises an angelica sinensis extract.
Angelica sinensis, root of Angelica sinensis (Oliv.) Diels of Umbelliferae. Also called dry angelica, cauda equiseti, Yunnan angelica, etc. Sweet, pungent, bitter and warm in nature. It enters liver, heart and spleen meridians. Has the effects of promoting blood circulation and tonifying blood. The angelica mainly contains volatile oil, organic acid and the like, and can play roles of oxidation resistance and inflammation resistance.
While the prior art such as CN102209526B discloses a composition containing an extract of Angelica acutiloba, it does not disclose an extract of Angelica acutiloba, nor does it disclose the efficacy and application of the compound extract containing Angelica acutiloba of the present invention.
In a preferred embodiment, the Chinese medicinal composition of the present invention comprises 10 to 25 parts by weight, preferably 10 to 15 parts by weight of the angelica sinensis extract.
Chinese medicinal composition
According to the application, the saffron extract, the ginseng extract, the lotus extract, the polygonum cuspidatum extract, the ligusticum wallichii extract and the angelica sinensis extract are combined for the first time, and all the medicines in the obtained compound traditional Chinese medicine composition supplement each other to achieve the effects of resisting aging and improving the skin.
The traditional Chinese medicine composition is suitable for the field of cosmetics. The present invention has unexpectedly found that a Chinese medicinal composition comprising saffron extract, ginseng extract, lotus extract, polygonum cuspidatum extract, ligusticum wallichii extract and angelica sinensis extract has antioxidant and/or anti-glycosylation effects. Therefore, the traditional Chinese medicine composition can be used as an efficacy additive to be added into cosmetics to assist in improving skin aging, oxidation, wrinkle problems and the like.
In one embodiment of the invention, the weight ratio of the saffron extract to the Chinese traditional medicine composition, the ginseng extract, the lotus extract, the giant knotweed extract, the ligusticum wallichii extract and the angelica sinensis extract is 0.1-0.5:1-3:1-2:0.5-2:1-2: 1-2. In a preferred embodiment, the weight ratio of saffron extract, ginseng extract, lotus extract, polygonum cuspidatum extract, ligusticum wallichii extract and angelica sinensis extract is 0.1:3:2:2:1: 1.
Extraction method
The traditional Chinese medicine extract is prepared by a solvent ultrasonic extraction method. For example, ethanol may be used as the extraction solvent. In a preferred embodiment, the extraction may be performed with 70 vol% ethanol.
In one embodiment, the extraction process may be performed in steps. For example, in the first step, 95 vol% ethanol is used for ultrasonic extraction, centrifugal filtration is carried out, and the filtrate is discarded; and secondly, performing ultrasonic extraction by using 70 vol% of ethanol, performing centrifugal filtration, concentrating the filtrate, and filtering to obtain the required extract. The extraction step is carried out for a period of up to 24 hours, but may be shorter. For example, the extraction process may be performed for 30 minutes to 1 hour.
External preparation for skin
The invention also relates to a skin external preparation, which comprises a traditional Chinese medicine composition containing saffron extract, ginseng extract, lotus extract, giant knotweed extract, ligusticum wallichii extract and angelica sinensis extract, and a cosmetically, dermatologically or pharmaceutically acceptable excipient.
In some preferred embodiments, the amount of the herbal composition of saffron extract, ginseng extract, lotus flower extract, polygonum cuspidatum extract, ligusticum wallichii extract and angelicae sinensis extract is 0.001-20% (w/w), preferably 0.008-10% (w/w), more preferably 0.01-5% (w/w), and most preferably 0.01-2% (w/w), based on the total weight of the skin external preparation.
The composition for external preparation for skin is a general concept of all ingredients generally used for the external part of skin, and may be, for example, a cosmetic composition or a pharmaceutical composition. The cosmetic composition may be a basic cosmetic, a face makeup cosmetic, a body cosmetic, a hair care cosmetic, etc., and the formulation thereof is not particularly limited and may be appropriately selected depending on the purpose.
The skin external preparation can be formulated into any suitable product form. Such product forms include, but are not limited to, aerosol sprays, creams, lotions, solids, liquids, dispersions, foams, gels, lotions, mousses, ointments, powders, patches, pomades, solutions, hand pump sprays, sticks, masks and towelettes. Such external skin preparations can be conveniently used for preparing or as cosmetic, dermatological or pharmaceutical topical application products by various methods well known in the art.
The composition for external skin preparations of the present invention may include one or more of the following ingredients: anti-allergic agents, antimicrobial agents, antioxidants, chelating agents, colorant depigmenting agents, emollients, emulsifiers, exfoliants, film formers, fragrances, humectants, insect repellents, lubricants, pharmaceutically active agents, moisturizers, light stabilizers, preservatives, skin protectants, skin penetration enhancers, sunscreens, stabilizers, surfactants, thickeners, viscosity modifiers, vitamins, or any combination thereof.
The cosmetically, dermatologically or pharmaceutically acceptable vehicle that can be used in the composition for external application to skin of the present invention is in the form of a water phase, an oil phase, a gel, a wax-in-water emulsion, an oil-in-water emulsion or a water-in-oil emulsion. The aqueous phase is a mixture of one or more water-soluble or dispersible components, which may be liquid, semi-solid, or solid at room temperature (25 ℃). The vehicle includes or may be in the form of a suspension, dispersion or solution in an aqueous or hydro-alcoholic vehicle, which may contain a thickening or gelling agent. The person skilled in the art can select suitable product forms, the components contained therein, based on the knowledge of the person skilled in the art.
The composition may comprise an aqueous phase which may contain water or a mixture of water and at least one hydrophilic organic solvent such as an alcohol, in particular a linear or branched lower monohydric alcohol containing from 2 to 5 carbon atoms, such as ethanol or propanol; polyols, such as propylene glycol, sorbitol, glycerol, panthenol or polyethylene glycols and mixtures thereof.
When the composition of the invention is in the form of an emulsion, the composition may also optionally comprise a surfactant.
The composition may also comprise film-forming polymers such as polyurethanes, polyacrylic acid homo-or copolymers, polyesters, hydrocarbon-based resins and/or silicone resins. The polymer may be dissolved or dispersed in a cosmetically acceptable vehicle and optionally combined with a plasticizer.
The compositions of the present invention may also comprise an oil phase containing oil-soluble or oil-dispersible components that are liquid at room temperature (25 ℃) and/or substances that are oily or waxy at room temperature, such as waxes, semisolids, gums, and mixtures thereof. The oil phase may also contain an organic solvent.
Typically liquid at room temperature, suitable oily substances include: hydrocarbon-based oils of animal origin, such as perhydrosqualene; hydrocarbon-based vegetable oils, such as liquid triglycerides of C4-10 fatty acids, e.g. heptanoic acid or octanoic acid triglycerides, or oils, e.g. sunflower oil, corn oil, soybean oil, grapeseed oil, castor oil, avocado oil, octanoic/decanoic acid triglycerides, jojoba oil; linear or branched hydrocarbons of mineral or synthetic origin, such as liquid paraffin and its derivatives, vaseline; synthetic esters and ethers, in particular esters of fatty alcohols, such as isopropyl myristate, 2-ethylhexyl palmitate, 2-octyldodecyl stearate, isostearyl isostearate; hydroxylated esters, such as isostearyl lactate, octyl hydroxystearate, octyl dodecyl hydroxystearate, heptanoates, octanoates and decanoates of fatty alcohols; polyol esters such as propylene glycol dicaprylate, neopentyl glycol diheptanoate, diethylene glycol diisononanoate, and pentaerythritol esters; c12-26-containing fatty alcohols, such as octyldodecanol, 2-butyloctanol, 2-hexyldecanol, 2-undecylpentadecanol, oleyl alcohol; fluoro and/or fluorosilicone oils based in part on hydrocarbons, silicone oils, volatile or non-volatile linear or cyclic polymethylsiloxanes which are liquid or semi-solid at room temperature, such as cyclic polydimethylsiloxanes and polydimethylsiloxanes, optionally containing phenyl groups, such as phenyltrimethicones, silicones and mixtures thereof.
The composition of the present invention may further comprise any component commonly used in the cosmetic field. These components include preservatives, aqueous phase thickeners (extract biopolymers, synthetic polymers) and fatty phase thickeners, fragrances, hydrophilic and lipophilic active agents and mixtures thereof.
The compositions of the invention may also comprise an additional particulate phase, which may be a pigment and/or a pearlescent agent and/or a filler used in cosmetic compositions.
Pigments may be present in the composition, suitable inorganic pigments include titanium oxide, zirconium oxide and cerium oxide as well as zinc oxide, iron oxide and ferric blue; suitable organic pigments include barium, strontium, calcium and aluminum lakes and carbon black.
Pearling agents may be present in the composition, suitable pearling agents include mica coated with titanium oxide, iron oxide or natural pigments.
Fillers may be present in the composition, suitable fillers include talc, silica, zinc stearate, mica, kaolin, nylon powder, polyethylene powder, teflon, starch, boron nitride, copolymer microspheres, such as silicone resin microbeads.
The oil phase of the compositions of the present invention may comprise one or more waxes, gums or mixtures thereof. Waxes include hydrocarbon-based waxes, fluoro waxes, and/or silicone waxes, and may be derived from vegetable, mineral, animal, and/or synthetic sources. Suitable waxes include beeswax, carnauba wax, candelilla wax, paraffin wax, microcrystalline wax, ozokerite; synthetic waxes include polyethylene waxes, silicone waxes containing C16-45. Gums are generally polydimethylsiloxanes or sodium carboxymethylcellulose or extracts, and semisolid substances are generally hydrocarbon-based compounds, such as lanolin and its derivatives.
The compositions of the present invention may be formulated into any suitable product form. Such product forms include, but are not limited to, aerosol sprays, creams, lotions, solids, liquids, dispersions, foams, gels, lotions, mousses, ointments, powders, patches, pomades, solutions, hand pump sprays, sticks, masks and towelettes. The compositions of the present invention may be conveniently used to prepare or as cosmetic, dermatological or pharmaceutical topical products by various methods well known in the art.
The composition for external skin preparations of the present invention may include one or more of the following ingredients: anti-allergic agents, antimicrobial agents, antioxidants, chelating agents, colorant depigmenting agents, emollients, emulsifiers, exfoliants, film formers, fragrances, humectants, insect repellents, lubricants, pharmaceutically active agents, moisturizers, light stabilizers, preservatives, skin protectants, skin penetration enhancers, sunscreens, stabilizers, surfactants, thickeners, viscosity modifiers, vitamins, or any combination thereof.
Detailed Description
The invention is further illustrated below with reference to specific examples. It is to be understood, however, that these examples are illustrative only and are not to be construed as limiting the scope of the present invention. Test methods in which specific conditions are not specified in the following examples are generally carried out under conventional conditions or under conditions recommended by the manufacturer. All percentages and parts are by weight unless otherwise indicated.
The sources and origins of the medicinal materials used in the following examples are as follows:
west safflower Beijing Wan drink factories, producing area Tibet;
fresh ginseng, Jingwan decoction piece factory, Jilin of origin;
jingwan decoction piece factory of flos Nelumbinis, Hunan of origin;
giant knotweed rhizome Beijing Wan decoction piece factory, Hubei of origin;
chuan Xiong Jingwan drink tablet factory, Sichuan of origin;
dang Gui Jing Wan decoction piece factory, Gansu of origin.
Example 1: preparation of saffron extract
Weighing 10g of saffron, carrying out ultrasonic extraction for 30min by using 10 times of 95% ethanol, carrying out centrifugal filtration, and removing the filtrate. The residue is treated with 20 times of 70% ethanol by ultrasonic treatment for 40min, and then centrifuged and filtered, and the filtrate is concentrated at 55 deg.C and then kept at 4 deg.C overnight. Taking out, centrifuging at 3 deg.C and 3500rpm for 15min, filtering with filter paper to obtain 1g/ml solution with solid content of 20.02% and 1% for use.
Example 2: preparation of fresh ginseng extract
Weighing 100g of fresh ginseng, pulverizing into coarse powder, performing ultrasonic extraction for 30min by using 10 times of 95% ethanol, performing centrifugal filtration, and removing filtrate. The residue is treated with 8 times of 70% ethanol by ultrasonic treatment for 40min, and then is subjected to centrifugal filtration, the filtrate is concentrated at 55 deg.C, and is kept stand at 4 deg.C overnight. Taking out, centrifuging at 3 deg.C and 3500rpm for 15min, filtering with filter paper to obtain 1g/ml solution with solid content of 2.43% and 1% for use.
Example 3: preparation of lotus extract
Weighing 100g of lotus, carrying out ultrasonic extraction for 30min by using 10 times of 95% ethanol, carrying out centrifugal filtration, and discarding the filtrate. The residue is treated with 20 times of 70% ethanol by ultrasonic treatment for 40min, and then centrifuged and filtered, and the filtrate is concentrated at 55 deg.C and then kept at 4 deg.C overnight. Taking out, centrifuging at 3 deg.C and 3500rpm for 15min, filtering with filter paper to obtain 1g/ml solution with solid content of 4.91%, and preparing into 1% solution.
Example 4: preparation of giant knotweed rhizome extract
Weighing 100g of giant knotweed rhizome, carrying out ultrasonic extraction for 30min by using 10 times of 95% ethanol, carrying out centrifugal filtration, and discarding the filtrate. The residue is treated with 20 times of 70% ethanol by ultrasonic treatment for 40min, and then centrifuged and filtered, and the filtrate is concentrated at 55 deg.C and then kept at 4 deg.C overnight. Taking out, centrifuging at 3 deg.C and 3500rpm for 15min, filtering with filter paper to obtain 1g/ml solution with solid content of 6.77%, and preparing into 1% solution.
Example 5: preparation of Ligusticum wallichii extract
Weighing 100g of rhizoma Ligustici Chuanxiong, ultrasonic extracting with 10 times of 95% ethanol for 30min, centrifuging, filtering, and discarding the filtrate. The residue is treated with 20 times of 70% ethanol by ultrasonic treatment for 40min, and then centrifuged and filtered, and the filtrate is concentrated at 55 deg.C and then kept at 4 deg.C overnight. Taking out, centrifuging at 3 deg.C and 3500rpm for 15min, filtering with filter paper to obtain 1g/ml solution with solid content of 5.72% and 1% solution for use.
Example 6: preparation of Angelica sinensis extract
Weighing 100g of angelica, carrying out ultrasonic extraction for 30min by using 10 times of 95% ethanol, carrying out centrifugal filtration, and discarding the filtrate. The residue is treated with 20 times of 70% ethanol by ultrasonic treatment for 40min, and then centrifuged and filtered, and the filtrate is concentrated at 55 deg.C and then kept at 4 deg.C overnight. Taking out, centrifuging at 3 deg.C and 3500rpm for 15min, filtering with filter paper to obtain 1g/ml solution with solid content of 33.35% and 1% for use.
Example 7: preparation of Chinese medicinal composition
The extract of example 1 in mass ratio: example 2 extract: example 3 extract: example 4 extract: example 5 extract: example 6 extracts (0.1:3:2:2:1:1) were mixed to prepare a Chinese medicinal composition, which was finally prepared into a solid content 1% solution for use.
Example 8: preparation of Chinese medicinal composition
The extract of example 1 in mass ratio: example 2 extract: example 3 extract: example 5 extract: example 6 extracts (0.1:3:2:1:1) were mixed to prepare a Chinese medicinal composition, which was finally prepared into a solid content 1% solution for use.
Example 9: preparation of Chinese medicinal composition
The extract of example 1 in mass ratio: example 3 extract: example 5 extract: example 6 extracts (0.1:2:1:1) were mixed to prepare a Chinese medicinal composition, which was finally prepared into a solid content 1% solution for use.
Example 10: preparation of Chinese medicinal composition
The extract of example 1 in mass ratio: example 2 extract: example 3 extract: example 4 extract: example 5 extract: example 6 extracts (0.5:1:2:1:1:1) were mixed to prepare a Chinese medicinal composition, which was finally prepared into a solid content 1% solution for use.
Example 11: preparation of Chinese medicinal composition
The extract of example 1 in mass ratio: example 2 extract: example 3 extract: example 4 extract: example 5 extract: example 6 extracts (0.2:1:1:0.5:1:1) were mixed to prepare a Chinese medicinal composition, which was finally prepared into a solid content 1% solution for use.
Example 12: preparation of Chinese medicinal composition
The extract of example 1 in mass ratio: example 2 extract: example 3 extract: example 4 extract: example 5 extract: example 6 extracts (0.1:2:1:0.5:1:1) were mixed to prepare a Chinese medicinal composition, which was finally prepared into a solid content 1% solution for use.
Example 13: evaluation of antioxidant Properties of Chinese medicinal extract
DPPH (diphenylbitter acyl radical) is a stable long-life radical, and the ethanol solution of DPPH is dark purple and has strong absorption near 517 nm. In the presence of free radical scavengers, DPPH light absorption is reduced due to its single electron pairing. The degree of discoloration of the DPPH ethanol solution is quantitatively related to the number of electrons accepted by the DPPH ethanol solution, so that the capacity of the antioxidant to remove free radicals or the antioxidant activity can be evaluated, and the higher the inhibition rate is, the better the antioxidant effect is.
The prepared extracts of examples 1 to 12 were mixed with distilled water to prepare 12.5ug/ml, 62.5ug/ml, and 312.5ug/ml of each 2ml, and the test was carried out according to the following method, and after 40min at room temperature, absorbance was measured at 517 nm. DPPH was obtained from Sigma, with an active concentration of 60 ug/ml.
The results are shown below.
TABLE 1
| Unit/ml | T | T0 | C | C0 |
| Sample (I) | 2 | 2 | － | － |
| Water (W) | － | － | 2 | 2 |
| DPPH | 2 | － | 2 | － |
| Anhydrous ethanol | － | 2 | － | 2 |
Wherein T is sample, T0 is sample control, C is blank, and C0 is blank control.
TABLE 2
The DPPH scavenging free radical results show that the extracts of examples 7-12 have better antioxidant capacity than the extracts of examples 1-6, wherein the extract of example 7 has the strongest antioxidant capacity, and the proportion of the complex extract is considered to be the best, followed by the extract of example 10. Example 9 the extract of example 9 has 2 removed chinese herbs and example 8 has 1 removed chinese herbs, but the extract of example 9 has better antioxidant effect than the extract of example 8, presumably because the extract of example 2, i.e. the fresh ginseng extract, has no significant antioxidant activity and at the same time the proportion of the extract of example 8 is larger. When 6 medicines are compounded, the composition has a synergistic effect.
Example 14: evaluation of anti-glycation Performance of Chinese medicinal composition
1. The experimental method comprises the following steps:
(1) tissue treatment: skin tissue (from 45-year-old male leg; purchased from Guangdong Boxi Biotechnology Co., Ltd.) was frozen in a liquid nitrogen tank, taken out, melted in hot water at 37 deg.C, and then frozen in liquid nitrogen, and this was repeated 5 times. The skin was removed, placed in a 24-well plate, washed 3 times with a buffer containing bis-anti-PBS (from Boshide), soaked in 75% ethanol for 5min, washed 3 times with a buffer containing bis-anti-PBS, and finally placed in a buffer containing bis-anti-PBS for 24 h.
(2) UVA irradiated tissue: in order to accelerate saccharification reaction, 1 ml/hole of saccharification reaction PBS buffer solution is added into a 24-hole plate, and tissues of other incubation systems except a blank control group are irradiated 7 days before saccharification reaction and are measured to be 10J/cm2The UVA irradiation (UVA irradiator, average intensity of irradiation of the UVA irradiator is 13.38mw/s, irradiation time of 10J/cm2 is 12min 27s), and after the irradiation is finishedAnd sealing the 24-hole plate by using a sealing film, placing the plate in a 45 ℃ oven for reaction for 72 hours, and repeating for 1 time after 72 hours.
(3) The operation was carried out in the following manner.
TABLE 3
Wherein the Blank Control (BC) is PBS buffer solution containing double antibody, the Negative Control (NC) is PBS buffer solution containing double antibody +0.5mM methylglyoxal, the Positive Control (PC) is PBS buffer solution containing double antibody +0.5mM methylglyoxal +3mM aminoguanidine sulfate, and the experimental group (S) is PBS buffer solution containing double antibody +0.5mM methylglyoxal + carnosine/example 7 extract. The experimental group (S) was divided into S1 group and S2 group. S1 corresponds to an externally sourced control product (currently a widely accepted source of efficacy by consumers), and group S2 is the extract of the present invention.
When the solution is changed, the BC group is changed into buffer solution containing the double-antibody PBS; changing the NC group into PBS buffer solution containing 0.5Mm methylglyoxal and double antibodies; the PC group was changed to PBS buffer solution containing 0.5Mm methylglyoxal, 3mM aminoguanidine sulfate and double antibody; the S group was changed to PBS buffer containing 0.5Mm methylglyoxal, 0.625% carnosine/extract of example 7 and double antibody, 3 replicates of each group were set up, the tissues were fixed with 4% formaldehyde at the time of harvest, and then immunohistochemistry.
(4) Immunohistochemical detection
The primary antibody kit in the immunohistochemical detection is Anti-carboxyymethyl Lysine antibody [ NF-1G ], purchased from abcam. The secondary antibody kit was VECTASTAIN ABC Kit (mouse IgG) from Velcro Laboratories (Vector Laboratories).
Baking sheets and dewaxing: the paraffin sections were placed in a 70 ℃ baking machine and baked for 4 hours.
Dewaxing and hydrating: soaking the slices in xylene for 10min, replacing xylene, repeating for 1 time, and sequentially soaking in anhydrous ethanol, 95% ethanol, and 75% ethanol for 5 min. The cells were washed 3 times with PBS buffer for 5min each time.
Antigen retrieval: and (3) placing the paraffin sections into 0.01M sodium citrate antigen retrieval solution, adopting high pressure retrieval, cooling, taking out, and washing for 5min each time for 3 times by using PBS buffer solution.
Blocking peroxidase: each section was incubated with 1 drop of 3% hydrogen peroxide at room temperature for 30min to block the activity of endogenous peroxidase, and washed 3 times with PBS buffer for 5min each.
Serum blocking: serum homologous to the secondary antibody was added dropwise and blocked at 37 ℃ for 1 h.
Primary antibody incubation: adding primary antibody working solution dropwise, incubating overnight at 4 deg.C, and washing with PBS buffer solution for 5min for 3 times.
And (3) secondary antibody incubation: adding secondary antibody working solution dropwise, incubating at 4 deg.C for 1h, washing with PBS buffer solution for 3 times, each time for 5 min.
Incubation of ABC complexes: dripping ABC complex solution, incubating at room temperature for 30min, and washing with PBS buffer solution for 5min each time for 3 times.
DAB dyeing: 1 drop of DAB solution prepared freshly was added to each section and observed for 5-30s under a microscope.
Counterdyeing: hematoxylin counterstain for 30 s.
And (3) dehydrating: dehydrating the slices with 75% ethanol, 95% ethanol, anhydrous ethanol, and anhydrous ethanol for 5min, soaking the slices in xylene for 10min, replacing xylene for 1 time, drying, sealing with neutral resin, drying in the sun, and observing.
2. The experimental results are as follows:
TABLE 4
Relative expression quantity of AGEs of in vitro skin (expressed quantity of AGEs of in vitro skin/average expression quantity of AGEs of in vitro skin of control group)
Wherein S1 is 0.625% carnosine and S2 is 0.625% of the extract of example 7.
According to the immunohistochemical detection result, the AGEs content in the NC group is obviously increased compared with that in the BC group, and the in vitro skin-based glycosylated skin model is successfully established. Compared with the NC group, the AGEs content of the S group is consistent with that of the aminoguanidine sulfate of the PC group, and is obviously reduced, which indicates that the carnosine and the extract of the example 7 have certain anti-glycation efficacy, and the statistical difference analysis shows that the AGEs content of the S group and the extract of the example 7 have no difference (p >0.5), which indicates that the anti-glycation efficacy of the carnosine and the extract of the example 7 has no difference.
The extracts of example 7 and examples 9 to 12 were used for the preparation of external preparations for skin. The skin external preparation is preferably a cosmetic composition such as a lotion, essence, cream, etc. The weight percentage of the compound extract in the skin external preparation is 0.0001-20% (w/w). Preferably 0.001-10% (w/w). More preferably 0.001-5% (w/w). Most preferably 0.01% to 5% (w/w).
The following are examples of specific applications of the Chinese medicinal composition in skin external preparations, and formulations and preparation methods of these dosage forms. In the tables, "-" indicates no addition.
Example 15: preparation of face cream
Example 16: preparation of the emulsion
Example 17: preparation of jelly
Example 18: preparation of astringent
Example 19: preparation of essence
Example 20: preparation of facial mask
Example 21: preparation of eye cream
Example 22: preparation of an aerosol (cleaning foam)
Example 23: preparation of the spray
Example 24: preparation of shower gel
Example 25: preparation of facial cleanser
Claims (11)
1. An anti-aging traditional Chinese medicine composition, comprising:
1-10 parts by weight of saffron extract,
15-40 parts by weight of a ginseng extract,
15-35 parts by weight of a lotus extract,
15-30 parts by weight of a giant knotweed extract,
10-25 parts by weight of a ligusticum wallichii extract,
10-25 parts by weight of an angelica extract,
wherein the stigma croci Sativi extract, Ginseng radix extract, flos Nelumbinis extract, rhizoma Polygoni Cuspidati extract, rhizoma Ligustici Chuanxiong extract, and radix Angelicae sinensis extract are prepared by solvent ultrasonic extraction method.
2. The Chinese medicinal composition of claim 1, wherein the weight ratio of the saffron extract, the ginseng extract, the lotus extract, the giant knotweed extract, the ligusticum wallichii extract and the angelica sinensis extract is 0.1-0.5:1-3:1-2:0.5-2:1-2: 1-2.
3. The traditional Chinese medicine composition of claim 2, wherein the weight ratio of the saffron extract to the ginseng extract to the lotus extract to the polygonum cuspidatum extract to the ligusticum wallichii extract to the angelica sinensis extract is 0.1:3:2:2:1: 1.
4. A Chinese medicinal composition according to any one of claims 1 to 3, wherein the extract is extracted with ethanol, preferably 70% ethanol by volume.
5. Use of a Chinese medicinal composition as claimed in any one of claims 1 to 3 for non-therapeutic purposes in combating skin ageing.
6. Use according to claim 5, wherein the anti-skin ageing is achieved by anti-oxidation and/or anti-glycosylation.
7. Use of the Chinese medicinal composition of any one of claims 1-3 for the preparation of a cosmetic for anti-skin aging.
8. Use according to claim 7, wherein the anti-skin ageing is achieved by anti-oxidation and/or anti-glycosylation.
9. A method of preparing the traditional Chinese medicine composition of any one of claims 1-3, the method comprising:
respectively preparing a saffron extract, a ginseng extract, a lotus extract, a giant knotweed extract, a ligusticum wallichii extract and an angelica sinensis extract by adopting a solvent ultrasonic extraction method;
the saffron extract, the ginseng extract, the lotus extract, the giant knotweed extract, the ligusticum wallichii extract and the angelica sinensis extract are combined according to parts by weight.
10. A skin external agent comprising the Chinese medicinal composition as claimed in claims 1 to 3.
11. The external preparation for skin as claimed in claim 10, which comprises 0.01-5% by weight of the Chinese medicinal composition as claimed in claim 1.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011591031.0A CN112641856B (en) | 2020-12-29 | 2020-12-29 | Anti-aging traditional Chinese medicine composition |
| PCT/CN2021/127252 WO2022142669A1 (en) | 2020-12-29 | 2021-10-29 | Anti-aging traditional chinese medicine composition, preparation method therefor, use thereof for non-therapeutic purpose, and use thereof in preparation of cosmetic |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011591031.0A CN112641856B (en) | 2020-12-29 | 2020-12-29 | Anti-aging traditional Chinese medicine composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112641856A true CN112641856A (en) | 2021-04-13 |
| CN112641856B CN112641856B (en) | 2022-03-25 |
Family
ID=75363625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011591031.0A Active CN112641856B (en) | 2020-12-29 | 2020-12-29 | Anti-aging traditional Chinese medicine composition |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN112641856B (en) |
| WO (1) | WO2022142669A1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112933023A (en) * | 2021-04-16 | 2021-06-11 | 上海家化联合股份有限公司 | Traditional Chinese medicine composition with whitening effect |
| CN114392323A (en) * | 2021-12-30 | 2022-04-26 | 上海家化联合股份有限公司 | Anti-glycation traditional Chinese medicine extract |
| WO2022142669A1 (en) * | 2020-12-29 | 2022-07-07 | 上海家化联合股份有限公司 | Anti-aging traditional chinese medicine composition, preparation method therefor, use thereof for non-therapeutic purpose, and use thereof in preparation of cosmetic |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108434033A (en) * | 2018-05-04 | 2018-08-24 | 广州市美晟美容化妆品有限公司 | A kind of lotus flower skin whitening, moisturizing anti-aging Essence and preparation method thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102631492B (en) * | 2012-04-24 | 2013-08-14 | 杨翠红 | Chinese medicinal composition for improving immunity and resisting fatigue |
| CN109294835A (en) * | 2018-10-23 | 2019-02-01 | 宕昌县福江源药业科技有限责任公司 | A kind of Chinese medicament healthcare wine formula of anti-aging |
| CN109453059B (en) * | 2018-12-26 | 2022-03-11 | 广州市科能化妆品科研有限公司 | Whitening cosmetic additive, whitening sleep mask and preparation method of whitening cosmetic additive |
| CN111329808A (en) * | 2020-04-03 | 2020-06-26 | 西安力邦医美科技有限公司 | Cosmetic composition with anti-glycosylation and anti-aging effects and application thereof |
| CN112641856B (en) * | 2020-12-29 | 2022-03-25 | 上海家化联合股份有限公司 | Anti-aging traditional Chinese medicine composition |
-
2020
- 2020-12-29 CN CN202011591031.0A patent/CN112641856B/en active Active
-
2021
- 2021-10-29 WO PCT/CN2021/127252 patent/WO2022142669A1/en active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108434033A (en) * | 2018-05-04 | 2018-08-24 | 广州市美晟美容化妆品有限公司 | A kind of lotus flower skin whitening, moisturizing anti-aging Essence and preparation method thereof |
Non-Patent Citations (6)
| Title |
|---|
| 徐承水: "人参抗衰老作用的实验研究", 《赣南师范学院学报》 * |
| 戚晓利等: "当归对D-半乳糖衰老模型小鼠抗氧化系统的研究", 《黑龙江医药科学》 * |
| 汪群红: "西红花对D-半乳糖致衰老大鼠模型抗氧化能力的影响", 《中华中医药学刊》 * |
| 胡懿淋: "中药虎杖水煎液对衰老小鼠学习、记忆功能的影响及机制", 《中外健康文摘》 * |
| 陈永兰等: "川芎对衰老小鼠超氧化物歧化酶和丙二醛及羟自由基的影响", 《中外医学研究》 * |
| 马珍珍等: "心脑宁片对D-半乳糖致亚急性衰老模型小鼠脑组织结构的影响", 《中国药业》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022142669A1 (en) * | 2020-12-29 | 2022-07-07 | 上海家化联合股份有限公司 | Anti-aging traditional chinese medicine composition, preparation method therefor, use thereof for non-therapeutic purpose, and use thereof in preparation of cosmetic |
| CN112933023A (en) * | 2021-04-16 | 2021-06-11 | 上海家化联合股份有限公司 | Traditional Chinese medicine composition with whitening effect |
| CN114392323A (en) * | 2021-12-30 | 2022-04-26 | 上海家化联合股份有限公司 | Anti-glycation traditional Chinese medicine extract |
| CN114392323B (en) * | 2021-12-30 | 2023-06-30 | 上海家化联合股份有限公司 | Anti-glycation traditional Chinese medicine extract |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022142669A1 (en) | 2022-07-07 |
| CN112641856B (en) | 2022-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112641856B (en) | Anti-aging traditional Chinese medicine composition | |
| JPH1036279A (en) | Fibroblast proliferation promoting agent containing vegetable extract | |
| EP1352640A1 (en) | Compositions for retarding skin aging | |
| JPH11335233A (en) | Melanogenesis inhibitor and cosmetic composition | |
| JPH11228339A (en) | Melanin generation suppresser and preparation for external use for skin | |
| JP2000169383A (en) | Antiallergic agent | |
| KR100564108B1 (en) | Cosmetic composition comprising plant extract having anti-aging effect | |
| WO2023124649A1 (en) | Anti-glycation traditional chinese medicine extract | |
| KR102369387B1 (en) | Cosmetic Composition for prevention of depilation or improvement of hair growth | |
| JP2003201214A (en) | Matrix metalloprotease activity inhibitor | |
| KR20170137544A (en) | Composition for improving skin condition comprising herb extracts mixture | |
| CN112472629A (en) | Alpinia officinarum and amomum tsao-ko sun-proof emulsion and preparation method thereof | |
| KR20170136911A (en) | Composition for improving skin condition comprising herb extracts mixture | |
| JP2971549B2 (en) | Cosmetics | |
| KR101415993B1 (en) | Composition for skin external application comprising Astragalus Membranaceus extract prepared by using pottery extractor | |
| KR20090065813A (en) | Method for the preparation of functional cosmetics from bokbunja wine processing waste | |
| KR20160003918A (en) | Cosmetic composition for enhancing skin elasticity or improving skin wrinkle containing herb extracts | |
| KR20070008831A (en) | Cosmetic composition comprising olive extract, oat extract and honey having skin refreshing effect | |
| JPH04312513A (en) | Cosmetic | |
| KR100564107B1 (en) | Cosmetic composition comprising plant extract having anti-aging effect | |
| KR20170136919A (en) | Composition for improving skin condition comprising herb extracts mixture | |
| KR20170137546A (en) | Composition for improving skin condition comprising herb extracts mixture | |
| KR20170136930A (en) | Composition for improving skin condition comprising herb extracts mixture | |
| KR20170136912A (en) | Composition for improving skin condition comprising herb extracts mixture | |
| JP2009249366A (en) | Collagen production promotor and anti-aging skin preparation for external use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |